Sort
8,912 grants matching “sars cov 2”
Implementation of a qPCR-based assay for the quantification of SARS-CoV-2-specific T cells in immunocompromised patients
$350,358Ernesto Guccione · Icahn School Of Medicine At Mount Sinai · UH3 · FY2024 · CA
Implementation of a qPCR-based assay for the quantification of SARS-CoV-2-specific T cells in immunocompromised patients
$350,358Ernesto Guccione · Icahn School Of Medicine At Mount Sinai · UH3 · FY2025 · CA
Project 1: Serological Correlates of SARS CoV2 Immunity and Disease
$350,149Ralph S Baric · Univ Of North Carolina Chapel Hill · U54 · FY2022 · CA
THE RATIONALE OF THIS WORK IS TO DETERMINE IF WHITE-TAILED DEER (WTD) CAN BECOME INFECTED AND TRANSMIT SARS-COV-2; THIS WILL BE CRITICAL INFORMATION FOR DECISION MAKERS IN TERMS OF RISK ASSESSMENT AND THE DEVELOPMENT AND IMPLEMENTATION OF PROPER MITIGATION AND CONTROL MEASURES. THERE IS CURRENTLY NO INFORMATION ON SARS-COV-2 INFECTION IN DEER; HOWEVER, THERE ARE STUDIES BASED ON VIRUS-HOST RECEPTOR INTERACTIONS SUGGESTING THAT DEER CAN BECOME INFECTED BY SARS-COV-2. THEREFORE, THE FIRST OBJECTIVE OF THIS WORK WILL BE TO STUDY SARS-COV-2 INFECTION OF DEER CELLS, THE SECOND OBJECTIVE WILL BE TO INFECT WTD ANIMALS WITH SARS-COV-2, AND THE THIRD OBJECTIVE WILL BE TO DEVELOP DIAGNOSTIC TOOLS FOR SARS-COV-2 INFECTION IN DEER. THIS PROJECT WILL DETERMINE WHETHER DEER CELLS CAN BE INFECTED BY SARS-COV-2 AND IF WTD CAN BECOME INFECTED AND TRANSMIT SARS-COV-2; ALSO, DIAGNOSTIC TOOLS FOR THE DETECTION OF SARS-COV-2 IN DEER WILL BE DEVELOPED. THIS WORK IS CRITICAL TO UNDERSTAND THE RISK THAT SARS-COV-2 POSES TO DEER AND FOR THE DEVELOPMENT OF RESPECTIVE TOOLS IN ORDER TO PROTECT THE HEALTH AND SECURITY OF OUR LIVESTOCK AND CITIZENS.
$350,000Kansas State University · · FY2020 · National Institute of Food and Agriculture
On-cell screening of mouse hybridomas for improved monoclonal antibody discovery
$350,000Rama Devudu Puligedda · Ocms Bio, Llc · R43 · FY2023 · GM
Project 1 Viral Genomics: surveillance, epidemiology, host response, and viral immunogenicity
$349,995Pardis Christine Sabeti · Broad Institute, Inc. · U19 · FY2020 · AI
High-throughput CRISPR-based Diagnostic Assay for Coronaviruses and Other Respiratory Diseases
$349,995Bruce W. Birren · Broad Institute, Inc. · U19 · FY2020 · AI
Long COVID as a putative subtype of chronic fatigue syndrome
$349,946Richa Saxena · Massachusetts General Hospital · R01 · FY2025 · AI
Aerosol Biology Small Animal Models
$349,884R Mark Buller · Washington University · U54 · FY2009 · AI
Three-dimensional Structures Of Biological Macromolecules
$349,588Bernard R Brooks · National Heart, Lung, And Blood Institute · ZIA · FY2021 · HL
Genomic Data Science Core
$349,251Shannon Soucy · Dartmouth College · P20 · FY2024 · GM
Scientific Project 1: Malaria Immune Responses to Pre-erythrocytic Malaria Vaccination or Infection
$349,031Kenneth D Stuart · Seattle Children'S Hospital · U19 · FY2024 · AI
Northern New England Clinical and Translational Research Network - N3C Initiative
$348,925Clifford J Rosen · Mainehealth · U54 · FY2022 · GM
Computational Design, Bioinformatics & Screening
$348,916Michael E. Johnson · University Of Illinois At Chicago · P01 · FY2008 · AI
Mechanisms of inflammation-triggered taste loss and its recovery
$348,801Hong Wang · Monell Chemical Senses Center · R01 · FY2023 · DC
Human Airway Biomimetics for RSV and Other Respiratory Viruses
$348,710Pedro A Piedra · Baylor College Of Medicine · U19 · FY2022 · AI
Validation of Smart Masks for Surveillance of COVID-19
$348,568Jesse Vincent Jokerst · University Of California, San Diego · R01 · FY2021 · DE
DeconDTN: Deconfounding Deep Transformer Networks for Clinical NLP
$348,541Trevor Cohen · University Of Washington · R01 · FY2024 · LM
Administrative Core
$348,252Clifford J Rosen · Mainehealth · U54 · FY2023 · GM
SARS-CoV-2 Variant Testing
$348,242Galit Alter · Massachusetts General Hospital · R01 · FY2021 · AI
HPV16 E6 Antibody Detection as an Early Marker of Oropharyngeal Cancer Among Men Living with HIV
$348,228Krystle A. Kuhs · University Of Kentucky · R01 · FY2021 · DE
Rapid development of SARS-CoV-2 specific therapeutics that leverage virus specific RNA elements
$348,164Jeffrey S Glenn · Stanford University · R01 · FY2020 · AI
Factors Responsible for the Development of Post-Acute Sequelae of Acute COVID Infection (PASC) In Hawaii
$348,102Gehan Devendra · University Of Hawaii At Manoa · U54 · FY2024 · MD
Using a Telehealth Model to Address Vaccine Hesitancy and Increase Vaccine Completion Among Communities in Southeastern Louisiana
$347,881Sara Abdul Sattar Al-Dahir · Xavier University Of Louisiana · U54 · FY2023 · MD
Investigation of the landscape of immunosequencing and its clinical relevance through novel immunoinformatic approaches
$347,880Li Zhang · University Of California, San Francisco · R01 · FY2023 · LM